ACHONDROPLASIA
Clinical trials for ACHONDROPLASIA explained in plain language.
Never miss a new study
Get alerted when new ACHONDROPLASIA trials appear
Sign up with your email to follow new studies for ACHONDROPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Breakthrough drug trial aims to help kids with dwarfism grow taller
Disease control CompletedThis Phase 3 study tested whether the drug infigratinib could help children with achondroplasia (the most common form of dwarfism) grow faster. The trial involved 114 children and teenagers aged 3 to 18 who took either the drug or a placebo. Researchers measured changes in height…
Matched conditions: ACHONDROPLASIA
Phase: PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Apr 02, 2026 03:56 UTC
-
New weekly shot shows promise for kids with dwarfism
Disease control CompletedThis trial tested whether a weekly injection could safely increase growth rate in children aged 2-11 with achondroplasia, a genetic condition that causes short stature. For one year, some children received the active injection while others received a placebo, followed by another …
Matched conditions: ACHONDROPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Ascendis Pharma Growth Disorders A/S • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New drug trial aims to help kids with dwarfism grow taller
Disease control CompletedThis study tested whether a daily oral medication called infigratinib could safely help children with achondroplasia grow taller. It involved 84 children aged 3-11 who had previously participated in a related study. Researchers measured growth rates, safety, and how the drug move…
Matched conditions: ACHONDROPLASIA
Phase: PHASE2 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC